IDEXX Laboratories - IDXX Stock Forecast, Price & News

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on IDXX shares. Barclays dropped their price objective on shares of IDEXX Laboratories from $700.00 to $582.00 and set an "overweight" rating on the stock in a report on Friday, August 5th. The Goldman Sachs Group upgraded shares of IDEXX Laboratories from a "neutral" rating to a "buy" rating and cut their price target for the company from $530.00 to $435.00 in a report on Thursday, July 21st. Atlantic Securities reduced their price objective on IDEXX Laboratories from $500.00 to $490.00 and set an "overweight" rating for the company in a research note on Wednesday, August 3rd. Stifel Nicolaus cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating and set a $415.00 target price for the company. in a research report on Wednesday, August 3rd. Finally, StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, July 25th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $483.57.

IDEXX Laboratories Trading Down 1.4 %

NASDAQ:IDXX traded down $5.52 during mid-day trading on Monday, reaching $390.91. The company's stock had a trading volume of 10,944 shares, compared to its average volume of 609,693. The stock has a market cap of $32.54 billion, a P/E ratio of 51.15, a P/E/G ratio of 5.28 and a beta of 1.14. The company has a debt-to-equity ratio of 1.68, a current ratio of 0.89 and a quick ratio of 0.61. The company's fifty day simple moving average is $370.31 and its two-hundred day simple moving average is $439.45. IDEXX Laboratories has a twelve month low of $318.50 and a twelve month high of $695.18.